Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Applied Genetic Technologies Corp (AGTC) USD0.001

Sell:$4.77 Buy:$4.79 Change: $0.11 (2.36%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$4.77
Buy:$4.79
Change: $0.11 (2.36%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$4.77
Buy:$4.79
Change: $0.11 (2.36%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).

Contact details

Address:
14193 Nw 119Th Terrace, Suite #10
ALACHUA
32615
United States
Telephone:
+1 (386) 4622204
Website:
https://www.agtc.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AGTC
ISIN:
US03820J1007
Market cap:
$129.45 million
Shares in issue:
25.89 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Scott Koenig
    Independent Chairman of the Board
  • Susan Washer
    President, Chief Executive Officer, Director
  • William Sullivan
    Chief Financial Officer
  • Matthew Feinsod
    Executive Vice President - Global Strategy and Development
  • Mark Shearman
    Chief Scientific Officer
  • Stephen Potter
    Vice President and Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.